

10-21-1999

OMB No. 0651-0011 (exp. 4/94)

MRD 10-19-99



101176791

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Novartis Corporation

2. Name and address of receiving party(ies)

Name: UCP Gen-Pharma AG

Internal Address: \_\_\_\_\_

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other \_\_\_\_\_

Street Address: Talstrasse 82

City: CH-4001 Zurich State: Switzerland

Execution Date: October 8, 1999

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No.(s)

07/707,265; 08/586 676

B. Patent No.(s)

5,079,229; 5,180,667; 5,861,377

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael W. Glynn

Internal Address: Novartis Corporation

Patent and Trademark Dept.

Street Address: 564 Morris Avenue

City: Summit State: NJ ZIP: 07901-1027

6. Total number of applications and patents involved: 5

7. Total fee (37 CFR 3.41) \$ 200

☐ Enclosed

☒ Authorized to be charged to deposit account and any other additional fees required.

8. Deposit account number:

19-0134 (in the name of Novartis Corporation)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

Melvyn M. Kassenoff

Name of Person Signing  
Reg. No. 26,389

Melvyn M. Kassenoff

Signature

October 12, 1999

Date

☐ Certificate of mailing on reverse side

Total number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:  
Commissioner of Patents & Trademarks, Box Assignments  
Washington, D.C. 20231

10/21/1999 DNGUYEN 00000049 190134 5079229

01 FC:581

200.00 CH

PATENT  
REEL: 010310 FRAME: 0485

## ASSIGNMENT

Whereas, Novartis Corporation, 564 Morris Avenue, Summit, NJ 07901-1027, a corporation of New York, and UCP Gen-Pharma AG, Talstrasse 82, CH-8001 Zurich, Switzerland, a corporation of Switzerland, are jointly the assignees and legal owners of the entire right, title and interest in (1) United States Patents 5,079,229 and 5,180,667 by virtue of an Assignment from Markus Gerhard Grütter, Dirk Heinz and Manfred Liersch to Ciba-Geigy Corporation and UCP Gen-Pharma AG dated February 6, 1989 and recorded in the Patent and Trademark Office on September 13, 1991 (Reel 5829, Frames 0394-0395), (2) United States Patent 5,861,377 by virtue of an Assignment from Hans Fritz, Christian Sommerhoff and Jutta Heim to Ciba-Geigy Corporation and UCP Gen-Pharma AG dated January 16, 1995 (in the case of Hans Fritz and Christian Sommerhoff) and January 23, 1995 (in the case of Jutta Heim) and recorded in the Patent and Trademark Office on April 27, 1998 (Reel 9152, Frames 0527-0529), (3) United States Patent Application No. 07/707,265 by virtue of an Assignment from Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, François Meyer, Ursula Seemüller, Hans Fritz, Walter Märki and Sefik Alkan to Ciba-Geigy Corporation and Plantorgan Werk Heinrich G.E. Christensen KG, Hornbusch 1, 2903 Bad Zwischenahn, Germany, a corporation of Germany, dated June 18, 1985 (in the case of François Meyer), July 8, 1985 (in the case of Ursula Seemüller and Hans Fritz) and June 13, 1985 (in the case of the other six assignors) and recorded in the Patent and Trademark Office on November 14, 1996 (Reel 8221, Frames 0812-0814) and an Assignment from said Plantorgan Werk Heinrich G.E. Christensen KG to UCP Gen-Pharma AG dated October 23, 1990 and recorded in the Patent and Trademark Office on February 25, 1991 (Reel 5608, Frames 0989-0992) and (4) United States Patent Application No. 08/586,676 by virtue of an Assignment from Hans Fritz and Christian Sommerhoff to Ciba-Geigy Corporation and UCP Gen-Pharma AG dated January 7, 1996 (in the case of Hans Fritz) and December 12, 1995 (in the case of Christian Sommerhoff) and recorded in the Patent and Trademark Office on November 12, 1996 (Reel 8214, Frames 0489-0491);

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and

Whereas, Novartis Corporation wishes to assign its entire interest in United States Patents 5,079,229, 5,180,667 and 5,861,377 and United States Patent Applications Nos. 07/707,265 and 08/586,676 to UCP Gen-Pharma AG, and said UCP Gen-Pharma AG wishes to acquire Novartis Corporation's interest in said patents and patent applications.


Now, therefore, Novartis Corporation hereby assigns to UCP Gen-Pharma AG and its successors and assigns its entire right, title and interest in (1)(a) United States Patents 5,079,229, 5,180,667 and 5,861,377, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including re-

issue patents), including the right to sue, and to obtain damages, for past infringement, said right, title and interest together with the right, title and interest currently held by UCP Gen-Pharma AG constituting the entire right, title and interest in said patents (including reissue patents), extensions and reexamination certificates and (2) (a) United States Patent Applications Nos. 07/707,265 and 08/586,676, (b) any and all continuations and divisions of said applications (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to UCP Gen-Pharma AG together with the right, title and interest currently held by UCP Gen-Pharma AG constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 8<sup>th</sup> day of October 1999.

Novartis Corporation

A handwritten signature in black ink, appearing to read 'Terry A. Barnett', is written over a horizontal line.

Terry A. Barnett  
President